By continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our Cookie Policy.
Overview
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.
NexoBrid® is our commercial orphan biologic drug for early non-surgical eschar removal of deep-partial and full-thickness thermal burns. It is a bromelain-based gel containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the United States, European Union, Japan, India, and other international markets. Its development is supported by the US Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS).
EscharEx® is MediWound’s leading biologic currently in development, utilizing the same active pharmaceutical ingredient found in NexoBrid. It is specifically designed for the debridement of chronic and hard-to-heal wounds. Promising results from Phase 2 studies demonstrate that EscharEx is highly effective and significantly faster than standard-of-care (SOC) treatments or placebo control in debriding venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). Furthermore, EscharEx exhibits a strong safety profile and excellent tolerability. The initiation of the Phase 3 study is anticipated in Q4 2023, marking a significant milestone in the development of EscharEx.
MW005 is an innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC). In a Phase I/II open-label, multicenter, randomized clinical trial conducted in the U.S., MW005 was shown to be safe, well-tolerated, and an effective treatment for BCC with patients demonstrating complete clinical and histological clearance of target lesions. The trial continues to progress, and we eagerly anticipate the release of results in Q3 2023, which will provide valuable insights into the future of MW005 as a promising therapy for low-risk Basal Cell Carcinoma.
Our Culture
"At MediWound, our exceptional team of dedicated professionals possesses the unique ability to turn visionary ideas into tangible realities. Our unwavering focus is to elevate the standard of care for our patients, ultimately enhancing their quality of life to a remarkable degree."
"It fills me with immense joy and fulfillment to witness the realization of my vision: making NexoBrid accessible to patients globally, revolutionizing burn care for thousands of individuals worldwide. As a physician, the ability to leave such a profound mark in the field of medicine is the ultimate reward, reflecting the profound impact we can have on people's lives."
The Total Solution
Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care. MediWound is committed to providing rapid and effective biologics that improve patient experiences and outcomes while reducing costs and unnecessary surgeries.
In-house Expertise
State of the Art Facility
Wide global network
Our Team
Chief Executive Officer
Founder
Chief R&D Officer
Chief Medical Officer
Chief Operating Officer
Chief Financial Officer
Executive Vice President & General Counsel
Executive Vice President of Strategy & Corporate Development
Medical Director
VP Plant Manager
VP Clinical Affairs
VP Research & Development
VP Quality
VP European Operations
Director of Regulatory Affairs
Chairman of the Board of Directors
Board Member
Chair of R&D Committee
Chair of Nominating and Governance Committee
Chair of Audit Committee
Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies
Venture Partner at aMoon, Israel’s largest HealthTech VC fund
Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon
Testimonials
Careers
Just us as we seek cure and advance care. Together we can improve patient outcomes and the standard of care.
"At MediWound, our talented team of professionals transform great ideas into reality. Our goal is to elevate the standard of care for our patients, resulting in a much better quality of life"
Chief Executive Officer
"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"
Founder
"At MediWound, science, technological innovation and deep industry knowledge expands our portfolio with new bio-therapeutic solutions for unmet medical needs"
Chief R&D Officer
“It is a privilege to take on this role during such an exciting and transformative time for MediWound. I look forward to working with this outstanding management team as we focus our efforts on advancing our clinical pipeline. I am excited to be part of a company that will meaningfully improve the lives of millions of patients worldwide.”
Chief Medical Officer
Chief Operating Officer
"In MediWound, we harness innovation, commitment, dedication and determination to change treatment paradigms to help patients’ in their times of pain. To see their relief is the most rewarding thing for us to cherish. It keeps driving us every single day"
Chief Financial Officer
"Creativity is thinking up new things. Innovation is doing new thing. At MediWound, we are privileged to have both, allowing us to improve our patients' lives and the standard of care."
Executive Vice President & General Counsel
Executive Vice President of Strategy & Corporate Development
Mr. Wolfenson co-founded and is also CEO of vTail Healthcare Telecommunications, a healthcare-wide digital platform with an initial focus on the advanced wound care market. He also recently served as a key Strategic Advisor to Origin, Inc. on the development of their Phase III-ready IonoJetTM technology with an initial indication of diabetic foot ulcers. Mr. Wolfenson is currently on the Board of Directors at SANO Diagnostics, after having served as their CEO. SANO Diagnostics is a point-of-care inflammation diagnostic platform with initial focus on chronic wounds. Mr. Wolfenson spent 13 years at Derma Sciences in roles of increasing responsibility, helping to build the company’s advanced wound care business prior to its acquisition by Integra Life Sciences. He began his career as an analyst at Accenture before moving on to roles at Bristol Myers Squibb. Mr. Wolfenson holds a Master of Business Administration from the Stephen M. Ross School of Business, University of Michigan. He holds a Bachelor of Arts in Economics, & Pre-Med from Franklin & Marshall College.
“As stated by Viktor Frankl (1949), I believe one should transcend the self to find meaning. Alleviating the burden of those suffering from severe burns or chronic wounds, provides such meaning.”
Medical Director
"Establishing a state of the art cGMP sterile facility that takes the pineapple stem and makes it a pharmaceutical drug is a life accomplishment"
VP Plant Manager
“Clinical trials are important for discovering new treatments for diseases, as well as new ways to detect, diagnose, and reduce the chance of developing diseases. I’m proud to be part of all discoveries achieved in the last 20 years in the clinical development of our products and having new therapies available to patients”
VP Clinical Affairs
"Deep and robust foundations, are the key to every solid building. I am proud to lead the pre-clinical as well as the Chemistry, Manufacturing and Controls (CMC) development at MediWound. By a team work, my group is establishing the foundations for turning vision to reality"
VP Research & Development
"Quality is a crucial component of becoming an excellent organization. It is what enable us to provide the value with assuring the quality of our products and the safeness of our patients"
VP Quality
VP European Operations
"Regulatory affairs are the final stamp for our products and we are keen to maintain it at the highest standard. I am proud of the experience, know-how and knowledge we have aquired over the years working with all the major health authorities and bringing NexoBrid to burn patients worldwide."
Director of Regulatory Affairs
Chairman of the Board of Directors
Board Member
Chair of R&D Committee
Chair of Nominating and Governance Committee
Chair of Audit Committee
Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies
Recently collaborated with Nordic Capital in a deal valued at $1.3 billion. He also founded Biopharmax, a global design and construction provider of manufacturing facilities and systems for biotechnology, pharmaceutical and synthesis API manufacturers. Mr. Shem-Tov will provide MediWound with his expertise in scaling up facilities and optimizing manufacturing processes.
Venture Partner at aMoon, Israel’s largest HealthTech VC fund
Mr. Moed has recently retired from Bristol Myers Squibb (BMS), as Senior Vice President, Corporate Strategy. He led the strategic direction of the company with close linkage to all its major businesses, functions, and geographies. His recent focus was on the $90 billion acquisition and integration of Celgene by BMS. He serves in Board and advisory roles supporting companies in the HealthTech sector. Mr. Moed with his experience as an executive in the life sciences industry will provide MediWound with his expertise in strategic development for life science innovations.
Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon
He holds the academic title of Professor of Surgery at the Icahn School of Medicine. He is a world leader in limb salvage and lower extremity wound healing. To date, he has been the principal investigator on over 70 clinical trials. He directs a clinical research program in the field of lower extremity wound healing and tissue repair and published extensively. He currently sits on the editorial board of WOUNDS and is a reviewer for other journals. Dr. Lantis will provide MediWound with his medical expertise in all aspects of wound care.